Loading...
Venlafaxine, a serotonin-noradrenaline reuptake inhibitor, has apparently been shown to be effective in treatment-resistant depressed patients in a controlled-case series, and slightly superior to selective serotonin reuptake inhibitors (SSRIs) in some controlled studies of general depressed patients. This double-blind, randomized, multicenter study from France is the first to demonstrate the superior efficacy of venlafaxine over an SSRI in treatment-resistant, nonchronic depression.
Researchers randomized 122 patients with less than eight months duration of depression and a history of two prior unsatisfactory antidepressant treatments at adequate dose and duration to receive 28-day treatment with venlafaxine (200 to 300 mg) or paroxetine (3…